Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma

J Vet Intern Med. 2007 Nov-Dec;21(6):1364-73. doi: 10.1892/07-057.1.

Abstract

Background: The optimal treatment after inducing complete remission (CR) in dogs with lymphoma has not been established.

Hypothesis: After inducing CR with L-asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisone (L-CHOP); consolidation with either half-body radiation therapy (HBRT); or lomustine (CCNU) and mechlorethamine, vincristine, procarbazine, prednisone (MOPP) would improve first remission duration compared with continuing a CHOP-based protocol for an additional 4 months.

Animals: Dogs with stage III-V lymphoma.

Methods: Prospective clinical trial in which dogs initially were treated with an 8-week induction protocol that consisted of L-CHOP. Dogs in CR after induction were then allocated to 1 of 2 consolidation arms. A chemotherapy consolidation arm consisted of 2 treatments with CCNU and 1 cycle of MOPP. A HBRT arm consisted of 2 sequential 8.0-Gy fractions to the cranial and caudal half-body separated by 30 days. Vincristine was given between fractions. Results of the consolidation arms also were compared with a historical group treated with the same 8-week induction protocol followed by CHOP therapy until week 24.

Results: Overall, 67% of the dogs were in CR after 8 weeks of induction chemotherapy and were compared. Fifty-two dogs were in the historical arm, 23 in the CCNU/MOPP arm, and 27 in the HBRT arm. No difference in first remission duration was found among groups. Median first remission duration for the historical, CCNU/MOPP, and HBRT arms were 307, 274, and 209 days, respectively (P = .28). Overall second CR rate was 82% and was not different among groups (all P > or = .58). Overall remission duration (P = .28) and survival time (P = .48) were not different among groups.

Conclusions and clinical importance: Consolidation with either CCNU/MOPP or HBRT showed no advantage over a standard CHOP-based protocol.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dog Diseases / drug therapy*
  • Dogs
  • Lymphoma / drug therapy
  • Lymphoma / veterinary*
  • Remission Induction*

Substances

  • Antineoplastic Agents